---

1.原文連結：
※過長無法點擊者必須縮網址
https://reurl.cc/GVGreD

2.原文內容：
Moderna’s closely watched early-stage human trial for a coronavirus vaccine
produced Covid-19 antibodies in all 45 participants, the biotech company
announced Monday.

Each participant was assigned to receive a 25 microgram, 100 mcg or 250 mcg
dose, with 15 people in each dose group. Study participants received two
doses of the potential vaccine via intramuscular injection in the upper arm
approximately 28 days apart. Data on a second dose was not available for the
250 mcg group, the company said.

At day 43, or two weeks following the second dose, levels of binding
antibodies in the 25 mcg group were at the levels generally seen in blood
samples from people who recovered from the disease, the company said.
Antibodies in the 100 mcg had antibodies that “significantly exceeded levels
” in recovered patients.

The vaccine also produced neutralizing antibodies against Covid-19 in at
least eight participants, the company said. Four participants were assigned
to receive a 25 microgram dose, while the other four received 100 mcg. Levels
of neutralizing antibodies were at or above levels in blood samples, the
company said. Data on neutralizing antibodies for the other participants were
not yet available, Moderna said.

“These interim Phase 1 data, while early, demonstrate that vaccination with
mRNA-1273 elicits an immune response of the magnitude caused by natural
infection starting with a dose as low as 25 μg,” Tal Zaks, the chief
medical officer at Moderna, said in s statement.

“When combined with the success in preventing viral replication in the lungs
of a pre-clinical challenge model at a dose that elicited similar levels of
neutralizing antibodies, these data substantiate our belief that mRNA-1273
has the potential to prevent COVID-19 disease and advance our ability to
select a dose for pivotal trials,” Zaks added.

There are formally approved treatments for Covid-19, which has killed at
least 315,225 and sickened 4.7 million people worldwide since emerging from
the Chinese city of Wuhan more than 4 months ago, according to data compiled
by Johns Hopkins University.

Moderna has been fast-tracking work with the National Institutes of Health,
an agency within the Department of Health and Human Services, to develop a
vaccine.

The company said the vaccine was generally safe and well tolerated.

The potential vaccine by Moderna contains genetic material called messenger
RNA, or mRNA, that was produced in a lab. The mRNA is a genetic code that
tells cells what to build — in this case, an antigen that may induce an
immune response for the virus.

The phase 1 trial took place at the Kaiser Permanente Washington Health
Research Institute in Seattle, Washington. It tested the vaccine on 45 males
and non-pregnant females between the ages of 18 and 55.



3.心得/評論：
※必需填寫滿20字

粗略翻譯
Moderna公布早期臨床試驗報告
45個受試者分為25mg ,100mcg, 250mcg不等劑量疫苗的組別
每組各15個
所有受試者除了250mcg的以外都隔一個月施打兩劑
在研究的第43天 25mcg的受試者體內的抗體量跟得過COVID-19又痊癒的人一樣
100mcg的受試者體內抗體量遠多於痊癒的人

國光生 高端疫苗又怎麼走?

-----補充一下-----
1.其他報導有指出"安全性,耐受性"都很好
2.打低劑量25mcg兩次就有不錯數量的抗體
3.FDA已經同意phase II trial 接下來七月準備phase III..這超速會不會年底前就上市?
--
--
※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 123.110.4.55 (臺灣)
※ 文章代碼(AID): #1UmddEDC (Stock)
※ 文章網址: https://www.ptt.cc/bbs/Stock/M.1589803470.A.34C.html